HMGB1 and liver dysplastic nodule: In this study, we utilized two therapeutic strategies to inhibit endogenous HMGB1 activity, by systemic overexpression of esRAGE or administration of recombinant HMGB1 A Box, and determined the impact on the development of experimental DN and the underlying mechanisms.